3-fluoro-4-(1H-pyrazol-1-yl)benzenesulfonyl chloride | 1097726-37-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 3-fluoro-4-(1H-pyrazol-1-yl)benzenesulfonyl chloride
• 英文别名: 3-Fluoro-4-(1H-pyrazol-1-yl)benzene-1-sulfonyl chloride；3-fluoro-4-pyrazol-1-ylbenzenesulfonyl chloride
• CAS: 1097726-37-8
• 化学式: C₉H₆ClFN₂O₂S
• mdl: MFCD12157425
• 分子量: 260.676
• InChiKey: RIBBTTJUTZPZML-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  16
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  60.3
• 氢给体数：
  0
• 氢受体数：
  4

文献信息

• [EN] INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X<br/>[FR] INHIBITION DE LA PEPTIDASE 9X SPÉCIFIQUE DE L'UBIQUITINE
  申请人：FORMA THERAPEUTICS INC

  公开号：WO2020139916A1

  公开（公告）日：2020-07-02

  The disclosure provides novel chemical compounds useful as inhibitors of ubiquitin specific peptidase 9X (USP9X). USP9X inhibiting compounds are useful in the treatment of disease and disorders associated with modulation of USP9X, such as cancer.

  该披露提供了一种新颖的化合物，可用作泛素特异性蛋白酶9X（USP9X）的抑制剂。抑制USP9X的化合物在治疗与调节USP9X相关的疾病和紊乱，如癌症，方面是有用的。
• INHIBITING UBIQUITIN SPECIFIC PEPTIDASE 9X
  申请人：FORMA Therapeutics, Inc.

  公开号：US20220041597A1

  公开（公告）日：2022-02-10

  FLT3-ITD and FLT3-TKD are the most frequent mutations in acute myeloid leukemia (AML) with the former associated with a poor prognosis. Here we show that inhibition of the deubiquitinase USP9X by its inhibitor WP1130 or EOAI3402143 (G9) induces apoptosis preferentially in cells transformed by these mutant kinases, including FLT3-ITD-positive AML cell line MV4-11 and primary AML cells. Mechanistically, WP1130 induced aggresomal translocation of the mutant kinases, particularly FLT3-ITD in its activated and autophosphorylated conformation, to block the downstream signaling events, which was aggravated by knock down of USP9X. Moreover, USP9X physically associated with FLT3-ITD to inhibit its K63-linked polyubiquitination, while FLT3-ITD induced tyrosine phosphorylation and degradation of USP9X through the ubiquitin/proteasome pathway. WP1130 or G9 also induced oxidative stress to stimulate stress-related MAP kinase pathways and DNA damage responses to activate in cooperation with inhibition of FLT3-ITD signaling the intrinsic mitochondria-mediated apoptotic pathway, which was synergistically enhanced by BH3 mimetics and prevented by overexpression of Bcl-xL or Mcl-1. Thus, USP9X represents a promising target for novel therapies against therapy-resistant FLT3-ITD-positive AML.